DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Whether Illinois Medicaid covers Wegovy, Zepbound, Ozempic, or Mounjaro for weight loss and type 2 diabetes, prior authorization rules, and routes when coverage is denied.
Coverage tightened in 2025 but Wegovy and Zepbound remain on formulary with PA. Submit prior authorization through your prescriber, not directly. Approval decisions typically take 3-10 business days; expedited reviews for urgent cases process within 72 hours. Denials are appealable; first-round appeals succeed roughly 30-40% of the time when supporting documentation is thorough.
If Illinois Medicaid denies coverage, the practical routes are: (1) manufacturer cash-pay channels like NovoCare Direct (Wegovy at $499/month) and LillyDirect (Zepbound at $549/month), (2) compounded semaglutide or tirzepatide via telehealth (lower price but not FDA-approved; supply tightening after the May 2026 shortage resolution), or (3) charity care through patient assistance programs offered by Novo Nordisk and Eli Lilly for low-income patients.
Illinois telehealth modernization act 2022 expanded scope. Major telehealth providers operating in Illinois include form health, ro body, sequence ww.
Strong MCO competition keeps coverage robust.
Editorial summary, not legal or medical advice. State Medicaid policies change frequently. Confirm current status with Illinois Medicaid member services or your prescriber.